Crossmark

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Published Online: 2019-06-10

Published Print: 2019-08

Authors

Markus, Richard

McBride, Helen J.

Ramchandani, Monica

Chow, Vincent

Liu, Jennifer

Mytych, Dan

Fanjiang, Gary
Funding

Funding for this research was provided by:

Amgen
License Information

Text and Data Mining valid from 2019-06-10

Version of Record valid from 2019-06-10
More Information

Article History

Received: 21 December 2018

First Online: 10 June 2019

Document is current